Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled phase 2 study. Specific aim is to evaluate feasibility and safety of anti-IL-1 (interleukin 1) treatment in the course of standard therapy for diabetic ketoacidosis in children and its effect on intracranial pressure.


Clinical Trial Description

Anakinra is a fully human IL-1ra (interleukin 1 receptor agonist) licensed in 2001 by FDA for the treatment of rheumatoid arthritis. It competitively binds to the IL-1 receptor, thus blocking IL-1 signaling. It is a short-acting agent that requires daily subcutaneous administration at 1-2 mg/kg, maximum 100 mg/dose. It has been effective in lowering HbA1c (glycated haemoglobin) in T2D (type 2 diabetes) and a randomized trial of anakinra in recent onset T1D (type 1 diabetes) is underway in Europe. Overall, anakinra has been used in adults and children with a good safety record, for more than 10 years. Infrequent side effects include infections, neutropenia, nausea, diarrhea, cardiopulmonary arrest, influenza-like symptoms, and production of anti-anakinra antibodies.

Study Design: A double-blinded placebo-controlled RCT (randomized controlled trial) with 2:1 allocation (14 active treatment vs. 7 placebo). Anakinra treatment will be given as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours immediately after confirmation of the diagnosis of DKA (diabetic keto-acidosis) and when laboratory safety parameters are available (CBC (complete blood count) and pregnancy test) and after a consent is obtained. Primary outcomes: Safety and tolerability of anti-IL-1 treatment (anakinra) during the initial 24 hr period of DKA treatment. Secondary outcomes: Optic nerve sheath diameter (cut-off to define cerebral edema: 4.5 mm); Changes in cytokines levels during the treatment with anakinra. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01477476
Study type Interventional
Source University of Colorado, Denver
Contact
Status Withdrawn
Phase Phase 2
Start date March 2012
Completion date April 22, 2016

See also
  Status Clinical Trial Phase
Completed NCT05160142 - Diabetes Inspired Culinary Education Early Phase 1
Withdrawn NCT05035368 - Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes Phase 2
Completed NCT01928329 - A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00999375 - Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF) Phase 2
Completed NCT04279613 - A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 Phase 1
Not yet recruiting NCT02117518 - Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients N/A
Terminated NCT01308437 - Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics Phase 3
Terminated NCT01652911 - A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation Phase 1/Phase 2
Completed NCT06242548 - How Type I Diabetes Responds to Different Diets (Normoglucidic or Ketogenic) During Physical Activity at Altitude N/A
Completed NCT00351650 - Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan N/A
Withdrawn NCT00361608 - Monitoring of Nocturnal Hypoglycemia Using EarlySense Monitoring Device N/A
Terminated NCT03653533 - Evaluation of the Function "Stop Before Hypoglycemia" on External Insulin Pump N/A
Completed NCT00340639 - Management of Type 1 Diabetes Among Adolescents N/A
Completed NCT02634216 - Effects of Capros in Patients With Type-1 Diabetes N/A
Completed NCT02002130 - The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes Phase 1
Withdrawn NCT01623388 - Epigenetic Modifications of Diabetes Mellitus Type I N/A
Completed NCT02612493 - Obesity and Metabolic Surgery in Patients With Type I Diabetes N/A
Completed NCT01843114 - Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects N/A
Withdrawn NCT01398670 - Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics Phase 3